洛阳市中医院执行湖北中成药省际联盟带量采购政策实施成效分析

目的：分析湖北中成药省际联盟带量采购政策执行以来洛阳市中医院中选中成药的使用现状和政策执行情况，为下一步推进全国中成药集采政策落地实施提供参考。方法：采用药物经济学方法对洛阳市中医院湖北中成药省际联盟带量采购政策实施前后相关中成药的使用情况、用药频度（DDDs）、日均费用（DDC）等数据的变化情况以及约定采购量的完成情况进行回顾性分析。结果：该院在湖北中成药省际联盟带量采购涉及的5个品种中，康复新液、百令片和丹参注射液的DDDs在集采后有所增加，其中涨幅最高的是丹参注射液，为39.13%；血塞通和血栓通的DDDs在集采后有所减少，未中选品种降幅均在90%左右；百令片、丹参注射液的DDC有所增加，其他品种均有所减少；除血栓通外，其他品种均已完成约定采购量，且采购量和使用量一致。结论：湖北中成药省际联盟带量采购政策的实施取得了一定成效，降低了患者用药负担和医保支出。下一步需不断探索和完善中成药集采管理方法，为全国中成药集中带量采购政策的落地实施做好充分准备。

Analysis on Implementation Effect of Volume-based Procurement Policy of Hubei Chinese Patent Medicine Inter-provincial Alliance of Luoyang Traditional Chinese Medicine Hospital

Objective: To analyze the use status and policy implementation of Chinese patent medicine in Luoyang Traditional Chinese Medicine Hospital since the implementation of the Hubei Chinese Patent Medicine inter-provincial alliance with volume-based procurement policy, so as to provide references for the next step to promote the implementation of the national centralized procurement policy of Chinese patent medicine. Methods: The pharmacoeconomic methods were used to retrospectively analyze the changes in data such as the use of related Chinese patent medicine, Defi ned Daily Doses (DDDs) and Defi ned Daily Dose Cost (DDC) before and after the implementation of the volume-based procurement policy of Hubei Chinese patent medicine in Luoyang Traditional Chinese Medicine Hospital, as well as the completion of the agreed purchase quantity. Results: Among the 5 varieties involved in volume-based procurement of Hubei Chinese Patent Medicine interprovincial alliance in the hospital, the DDDs of Kangfuxin solution, Bailing Tablet and Salvia Miltiorrhiza injection increased after volume-based procurement, and the highest increase was Salvia Miltiorrhiza injection,which was 39.13%, the DDDs of Xuesaitong and Xueshuantong decreased after volume-based procurement, and the decrease of unselected varieties was about 90%. The DDC of Bailing tablets and Salvia Miltiorrhiza injection increased, while that of other varieties decreased. Except Xueshuantong, other varieties had completed the agreed purchase quantity, and the purchase quantity was consistent with the usage. Conclusion: The implementation of the procurement policy of Chinese patent medicine in the Hubei inter-provincial alliance has achieved certain eff ects, reducing the burden of medication for patients and medical insurance expenditure. In the next step, it is necessary to continuously explore and improve the management method of volume-based procurement of Chinese patent medicine, so as to make full preparations for the implementation of the national centralized volume-based procurement policy of Chinese patent medicine.